Catalyst Pharmaceuticals Stock Performance
| CPRX Stock | USD 25.87 0.13 0.51% |
On a scale of 0 to 100, Catalyst Pharmaceuticals holds a performance score of 7. The firm shows a Beta (market volatility) of 1.24, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Catalyst Pharmaceuticals will likely underperform. Please check Catalyst Pharmaceuticals' potential upside, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Catalyst Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Catalyst Pharmaceuticals are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Catalyst Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 6.23 | Five Day Return 15.53 | Year To Date Return 19.61 | Ten Year Return 523.24 | All Time Return 321.97 |
1 | Acquisition by Harper Molly of 1333 shares of Catalyst Pharmaceuticals subject to Rule 16b-3 | 12/27/2024 |
2 | Disposition of 8667 shares by Del Carmen Jeffrey of Catalyst Pharmaceuticals subject to Rule 16b-3 | 12/31/2024 |
3 | Disposition of 10600 shares by Daly Richard J of Catalyst Pharmaceuticals subject to Rule 16b-3 | 01/02/2025 |
4 | Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE Patent Litigation with Teva Pharmaceuticals | 01/08/2025 |
5 | Insider Trading | 02/13/2025 |
6 | Disposition of 2353 shares by Elsbernd Brian of Catalyst Pharmaceuticals subject to Rule 16b-3 | 02/14/2025 |
7 | Disposition of 1574 shares by Daly Richard J of Catalyst Pharmaceuticals subject to Rule 16b-3 | 02/19/2025 |
8 | Disposition of 4000 shares by Daly Richard J of Catalyst Pharmaceuticals subject to Rule 16b-3 | 02/24/2025 |
9 | Catalyst Pharmaceuticals Inc Q4 2024 Everything You Need To Know Ahead Of Earnings | 02/25/2025 |
10 | Heres Whats Driving Catalyst Pharmaceuticals Stock 8 percent Higher Today | 02/27/2025 |
11 | Catalyst Pharmaceuticals Receives Overweight Rating from Stephens | 02/28/2025 |
12 | Disposition of 30423 shares by Del Carmen Jeffrey of Catalyst Pharmaceuticals at 22.89 subject to Rule 16b-3 | 03/03/2025 |
13 | We Think Catalyst Pharmaceuticals Robust Earnings Are Conservative | 03/05/2025 |
14 | Disposition of 180096 shares by Ingenito Gary of Catalyst Pharmaceuticals at 21.67 subject to Rule 16b-3 | 03/06/2025 |
15 | Bank of New York Mellon Corp Raises Holdings in Catalyst Pharmaceuticals, Inc. - Defense World | 03/13/2025 |
16 | Advisors Asset Management Inc. Has 3.47 Million Holdings in Catalyst Pharmaceuticals, Inc. | 03/21/2025 |
17 | Is Catalyst Pharmaceuticals Attracting Institutional Attention | 03/24/2025 |
| Begin Period Cash Flow | 298.4 M |
Catalyst |
Catalyst Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 2,191 in Catalyst Pharmaceuticals on December 25, 2024 and sell it today you would earn a total of 383.00 from holding Catalyst Pharmaceuticals or generate 17.48% return on investment over 90 days. Catalyst Pharmaceuticals is currently generating 0.3261% in daily expected returns and assumes 3.3461% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Catalyst, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Catalyst Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Catalyst Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Catalyst Pharmaceuticals, and traders can use it to determine the average amount a Catalyst Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0974
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CPRX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.35 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.33 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Catalyst Pharmaceuticals is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Catalyst Pharmaceuticals by adding it to a well-diversified portfolio.
Catalyst Pharmaceuticals Fundamentals Growth
Catalyst Stock prices reflect investors' perceptions of the future prospects and financial health of Catalyst Pharmaceuticals, and Catalyst Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Catalyst Stock performance.
| Return On Equity | 0.29 | ||||
| Return On Asset | 0.18 | ||||
| Profit Margin | 0.33 % | ||||
| Operating Margin | 0.44 % | ||||
| Current Valuation | 2.43 B | ||||
| Shares Outstanding | 121.45 M | ||||
| Price To Earning | 23.62 X | ||||
| Price To Book | 4.04 X | ||||
| Price To Sales | 6.36 X | ||||
| Revenue | 491.73 M | ||||
| Gross Profit | 421.11 M | ||||
| EBITDA | 195.12 M | ||||
| Net Income | 163.89 M | ||||
| Cash And Equivalents | 220.79 M | ||||
| Cash Per Share | 2.15 X | ||||
| Total Debt | 2.79 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 10.79 X | ||||
| Book Value Per Share | 6.02 X | ||||
| Cash Flow From Operations | 143.6 M | ||||
| Earnings Per Share | 1.31 X | ||||
| Market Capitalization | 3.13 B | ||||
| Total Asset | 851.41 M | ||||
| Retained Earnings | 285.16 M | ||||
| Working Capital | 502.93 M | ||||
| Current Asset | 59.9 M | ||||
| Current Liabilities | 3.44 M | ||||
About Catalyst Pharmaceuticals Performance
Evaluating Catalyst Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Catalyst Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Catalyst Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 103.60 | 59.85 | |
| Return On Tangible Assets | 0.24 | 0.25 | |
| Return On Capital Employed | 0.27 | 0.28 | |
| Return On Assets | 0.19 | 0.20 | |
| Return On Equity | 0.23 | 0.24 |
Things to note about Catalyst Pharmaceuticals performance evaluation
Checking the ongoing alerts about Catalyst Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Catalyst Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Catalyst Pharmaceuticals had very high historical volatility over the last 90 days | |
| Over 83.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from kalkinemedia.com: Is Catalyst Pharmaceuticals Attracting Institutional Attention |
- Analyzing Catalyst Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Catalyst Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Catalyst Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Catalyst Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Catalyst Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Catalyst Pharmaceuticals' stock. These opinions can provide insight into Catalyst Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.